On Jan. 29th, Sanofi-Aventis, a European pharmaceutical group and Large Shareholder at Regeneron Pharmaceuticals Inc (NASDAQ:REGN), filed a Form 4 report at the U.S.
Keep Reading →
January 29 - Insider Trading, News - Comments
Abrams Capital Management, led by David Abrams significantly trimmed its stake in Engility Holdings Inc (NYSE:EGL).
Keep Reading →
December 30 - Hedge Funds, News - Comments
To me, flu season is a lot like Christmas; there's a defined time period when we expect it to occur, yet it seems to appear earlier and earlier every year.
Keep Reading →
September 23 - News - Comments
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), a developer and marketer of RNA-based novel drugs to treat a variety of diseases, has been one of the best performing stocks in the ...
Keep Reading →
September 20 - News - Comments
Shares of drug delivery systems manufacturer Unilife Corp (NASDAQ:UNIS) recently rallied after it announced a long-term contract to sell prefilled syringes to pharma giant Sanofi...
Keep Reading →
September 18 - News - Comments
There is perhaps nothing scarier than a cancer diagnosis.
Keep Reading →
September 17 - News - Comments
More than anything, biotech companies need investors who are true believers in their products.
Keep Reading →
September 17 - News - Comments
French drugmaker Sanofi SA (ADR) (NYSE:SNY) counted that much money in its coffers as of the end of June, including cash, cash equivalents, and short-term investments.
Keep Reading →
September 17 - News - Comments
In the world of small biotech companies, investors are always fishing for the next small fish to be gobbled up by a bigger one since the industry is well-known for its hefty acquisition...
Keep Reading →
September 16 - News - Comments
Looking for the best-performing sector in this year's big market rally? It may just be the biotech sector, which has erupted with astronomical gains in 2013.
Keep Reading →
September 16 - News - Comments
There were definitely some good parts in what Keryx Biopharmaceuticals (NASDAQ:KERX) had to say at this week's Stifel Nicolaus Weisel Healthcare Conference in Boston.
Keep Reading →
September 15 - News - Comments
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
September 14 - News - Comments
In my opinion, the Nike+ FuelBand released by Apple Inc. (NASDAQ:AAPL) and NIKE, Inc. (NYSE:NKE) last year was a seminal product in health care tech.
Keep Reading →
September 11 - News - Comments
Unilife Corp (NASDAQ:UNIS) will release its quarterly report on Tuesday, but investors already have reason to believe that the company won't make a profit.
Keep Reading →
September 9 - News - Comments
Peregrine Pharmaceuticals (NASDAQ:PPHM) will release its latest quarterly report on Monday, and investors are under no illusions that the company will avoid losing money again...
Keep Reading →
September 5 - News - Comments
As an investor in the health care sector, it can sometimes feel like everything -- and everyone -- is out to get you.
Keep Reading →
August 30 - News - Comments
Allergan, Inc. (NYSE:AGN), the diversified health care giant best known for Botox, boasts an impressive portfolio of products.
Keep Reading →
August 30 - News - Comments
In an attempt to further simplify its business and unlock shareholder value, Pfizer Inc. (NYSE:PFE) has been busy divesting itself of non-core assets.
Keep Reading →
August 29 - News - Comments
Eli Lilly & Co. (NYSE:LLY) recently rose nearly 3% following positive phase 3 results for cancer drug necitumumab.
Keep Reading →
August 27 - News - Comments
Peregrine Pharmaceuticals (NASDAQ:PPHM), a developmental stage biotech focusing on oncology treatments, recently announced that its lead drug candidate, bavituximab, was heading...
Keep Reading →
August 23 - News - Comments
Once upon a time in a regulatory environment far, far away, there was a cholesterol-fighting drug named Lipitor from Pfizer Inc. (NYSE:PFE).
Keep Reading →
August 21 - News - Comments
It's a disease that doesn't often find itself in the spotlight, but multiple sclerosis is quickly becoming an ailment that drugmakers are focusing their efforts on to make a quality...
Keep Reading →
August 19 - News - Comments
Earlier this year, in May, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was soaring on news of FDA approval of the Eylea injection.
Keep Reading →
August 12 - News - Comments
August might be hot for most of the country, but the first full week of the month wasn't so hot for some stocks.
Keep Reading →
August 12 - News - Comments
With the full implementation of the individual portion of the Patient Protection and Affordable Care Act less than five months away, physicians and doctor's offices around the...
Keep Reading →
August 12 - News - Comments
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) closed Tuesday down over 6% following a second quarter report that missed estimates.
Keep Reading →
August 9 - News - Comments
Currently existing immunomodulatory drugs that treat Multiple Sclerosis only work to treat relapse or attacks, manage symptoms, or modify the course of the disease.
Keep Reading →
August 8 - News - Comments
The Motley Fool's readers have spoken, and I have heeded their cries.
Keep Reading →
August 7 - News - Comments
As human beings it can sometimes be difficult for us to see the good in a bad situation.
Keep Reading →
August 7 - News - Comments
Believe it or not, 2013 is getting close to being two-thirds of the way over. Many pharmaceutical firms have enjoyed great stock returns and nice profits thus far in the year.
Keep Reading →
August 6 - News - Comments
Zoetis will release its quarterly report on Tuesday, and investors will get their first look at the company as a completely independent business entity.
Keep Reading →
August 5 - News - Comments
Around four in 10 Americans live in places where smog can impact their health.
Keep Reading →
August 5 - News - Comments
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will release its quarterly report on Tuesday, and the company's stock has been on an absolute tear over the past year.
Keep Reading →
August 2 - News - Comments
Keryx Biopharmaceuticals (NASDAQ:KERX) announced its second-quarter results before the market opened on Thursday.
Keep Reading →
August 1 - News - Comments
Diabetes is one of the world's most dangerous and fastest-growing afflictions.
Keep Reading →
August 1 - News - Comments
Hidden beneath all the numbers and metrics in Biogen Idec Inc (NASDAQ:BIIB)'s recent earnings report is a key confirmation of a shifting market in the treatment of multiple sclerosis...
Keep Reading →
August 1 - News - Comments
It’s estimated that 30% to 40% of adults in the world experience some degree of insomnia every year. Most of these cases aren’t chronic and do not require medication.
Keep Reading →
August 1 - News - Comments
Three months ago after Questcor Pharmaceuticals Inc (NASDAQ:QCOR) announced its first-quarter financial results, I asked if those results were as bad as they looked.
Keep Reading →
July 31 - News - Comments
We often take sleep, the number of hours we get to sleep, or the quality of sleep we get, for granted.
Keep Reading →
July 29 - News - Comments
Multiple myeloma is a cancer of plasma cells, a type of white blood cell present in bone marrow.
Keep Reading →
July 26 - News - Comments
The "people familiar with the matter" are out in full force spouting off about who's bidding for Onyx Pharmaceuticals, Inc.
Keep Reading →
July 19 - News - Comments
The Food and Drug Administration cancelled an advisory meeting planned for Merck & Co., Inc. (NYSE:MRK)’s post-surgery drug sugammadex.
Keep Reading →
July 19 - News - Comments
Sanofi SA (ADR) (NYSE:SNY) appeared at the American Diabetes Association meeting last month, touting data for the new insulin U300 and a combo therapy involving its approved drugs...
Keep Reading →
July 18 - News - Comments
At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide.
Keep Reading →
July 12 - News - Comments
The Orphan Drug pipeline of BioMarin Pharmaceutical Inc.
Keep Reading →
July 11 - News - Comments
At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide.
Keep Reading →
July 10 - News - Comments
The U.S. military has a reputation as a somewhat secretive organization. But in one respect at least, the Pentagon ranks among our most transparent government agencies.
Keep Reading →
July 8 - News - Comments
Imagine finding out that you have a disease that only a handful of people around the world have. Kirstie and Catherine Fields don't have to imagine it.
Keep Reading →
July 5 - News - Comments
The prescription-drug market currently generates a whopping $950 billion in annual sales, and that figure is likely to grow to $1.2 trillion by 2016.
Keep Reading →
July 3 - News - Comments
Healthcare stocks have rallied over the past couple years, and for good reason.
Keep Reading →
June 28 - News - Comments
